Trade Surface Oncology - SURF CFD

Surface Oncology Company profile

About Surface Oncology Inc

Surface Oncology, Inc. is a clinical-stage, immuno-oncology company focused on developing antibody therapies focused on the tumor microenvironment. The Company is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Its pipeline includes two wholly owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a pre-clinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase I) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Surface Oncology Inc revenues decreased 98% to $2.7M. Net loss totaled $78.5M vs. income of $59.3M. Revenues reflect License-related revenue decrease of 97% to $2.7M, Collaboration revenue - related party decrease from $38.6M to $0K. Net loss reflects Research and development - Balancing increase of 34% to $48.5M (expense), Stock-based Compensation in SGA increase of 24% to $6.1M (expense).